Refine your search

Search Results within category "Kidney & Urinary System"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Kidney & Urinary System"


5 Study Matches

Site for A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in subjects with IgA nephropathy

This study will evaluate the safety and effectiveness of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04905212
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of IgA nephropathy confirmed by biopsy
≥ 18 years old and ≤ 70 years old
Able and willing to complete all study visits and tests
Woman of childbearing potential agreeable to use an effective form of birth control
Exclusion Criteria:
History of kidney or other organ transplant
received systemic glucocorticoids or immunosuppressive therapy in previous 3 months
previous or current diagnosis of active tuberculosis
malignant tumor within 10 years
Kidney & Urinary System
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For 18-025, EA8143 A Phase 3 Study Comparing Perioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy

Site For 18-025, EA8143 A Phase 3 Study Comparing Perioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
Kathleen Rizzo at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03055013
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Newly Diagnosed higher risk RCC of any histology
No clinical or radiological evidence of distant metastases
No concurrent or prior systemic or local anti-cancer therapy for RCC is permitted
Age must be greater than or equal to 18 years old
ECOG Performance status must be 0 or 1
Exclusion Criteria:
Women must not be pregant or breast feeding
History of RCC that was resected with curative intent within the past 5 years
Prior or current prostate cancer is excluded
Active known or suspected autoimmune disease
Uncontrolled adrenal insufficiency
Kidney & Urinary System, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

PSCI 21-148 A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human open-label, dose-escalation and expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03845166
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cytologically or histologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:
Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology.
Exclusion Criteria:
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment
Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor
Receipt of any type of anticancer antibody (including investigational antibody), systemic chemotherapy, or hormonal anticancer therapy.
Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Kidney & Urinary System
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase III, Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy

To evaluate the effectiveness and safety of obinutuzumab compared to tacrolimus in patients with primary membranous nephropathy
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04629248
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of primary membranous nephropathy
age 18-75
ability to comply with requried study procedures
stable blood pressure
Exclusion Criteria:
secondary cause of membranous nephropathy
uncontrolled blood pressure
kidney transplant or dialysis
Type 1 or type 2 diabetes
Kidney & Urinary System
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer

Upper tract urothelial cancer (UTUC) is a recurrent disease. The current standard treatment for most UTUC patients requires surgery either removing some of the ureter in each operation or radical nephroureterectomy (RNU-removal of kidney and ureter) but the role of minimally invasive & kidney- preserving methods is increasing. The use of TOOKAD (padeliporfin) was investigated in a Phase 1 clinical study in the minimally-invasive treatment of UTUC with the goal of identifying safe laser/light exposure and signs that the tumor has been reduced or eliminated. Early results from this study have been highly promising, revealing the effects of tumor removal with a positive safety profile, indicating the potential role of TOOKAD (padeliporfin) in the treatment of low-grade UTUC disease. This Phase 3 study is designed to provide confirmation of the observed Phase 1 findings. Patients are expected to remain in the study for 25 to 28 months. Participation in this study will include up to 9 study visits to Hershey Medical Center and 2 phone visits.
Kathleen Lehman at KLehman3@pennstatehealth.psu.edu or 717-531-5930
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04620239
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
New or recurrent low-grade, non-invasive UTUC disease
Biopsy-proven disease. A concurrence of the central pathology reader will be required for eligibility.
Up to 2 biopsy-proven sites of low-grade involvement. Please contact site for tumor dimension criteria.
Karnofsky Performance Status ≥ 50%
Adequate organ function defined by baseline Lab testing
Exclusion Criteria:
Current high-grade or muscle invasive (>pT1) urothelial carcinoma of the bladder
Carcinoma in situ (CIS) current or previous in the upper urinary tract
History of invasive T2 or higher urothelial cancer in past 2 years
Participation in another clinical study involving an investigational product within 1 month before study entry
BCG or local chemotherapy treatment in the upper urinary tract within 2 months prior to inclusion
Kidney & Urinary System, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA